Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age

Leukemia. 2021 Dec;35(12):3636. doi: 10.1038/s41375-021-01357-4.
No abstract available

Publication types

  • Published Erratum